1. Approximately what percentage of patients with psoriatic arthritis (PsA) report that they receive no therapy or topical therapy only for the management of their disease?

2. What do the three sets of current clinical practice guidelines for managing PsA have in common?

3. According to current guidelines from the European League Against Rheumatism (EULAR), what is the recommended treatment target for the majority of patients with PsA?

4. How does EULAR define “sustained remission”?

5. According to ACR/NPF guidelines, when are NSAIDs recommended in patients with PsA?

6. All of the following therapies are currently FDA-approved for the treatment of PsA except:

7. Approximately what percentage of patients with PsA who initiate therapy with a TNF inhibitor will be on that same biologic 5 years later?

8. Kevin is a 48-year-old patient of yours with mild psoriasis who was diagnosed with PsA 9 months ago. He initiated therapy with etanercept, a TNF inhibitor, but his condition has not improved. Based upon current ACR/NPF guidelines, which of the following would be the most appropriate biologic to try next?

9. When should targeted synthetic DMARDs be considered as treatment options in patients with PsA?

10. Which of the following is the most appropriate definition of the term “omics”?